Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axcella Health Inc.AXLA · Entity 116059 | Director | May 20, 2021 | May 24, 2021 |
| Moderna, Inc.MRNA · Entity 2025 | President | September 14, 2026 | September 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axcella Health Inc.
Report date May 20, 2021 · Filed May 24, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.24 · Expires 2031-05-19 | Direct | 20,000 |
Reported balance
After 2021-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-20 · Grant · Acquired 20,000 · Balance 20,000 F1: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting.
Moderna, Inc.
Report date September 14, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,562,029 |
Ending reported balance
After 2026-09-15 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-09-14 · Exercise / conversion · Acquired 76,453 · Balance 1,566,152 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. Row 2 · 2026-09-14 · Sale · Disposed 40,294 · Balance 1,525,858 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.99 to $144.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Row 3 · 2026-09-15 · Exercise / conversion · Acquired 76,452 · Balance 1,602,310 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. Row 4 · 2026-09-15 · Sale · Disposed 40,281 · Balance 1,562,029 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.97 to $146.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.21 · Expires 2027-02-23 | Direct | 382,262 |
Reported balance
After 2026-09-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-14 · Exercise / conversion · Disposed 76,453 · Balance 382,262 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F5: This option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.21 · Expires 2027-02-23 | Direct | 305,810 |
Reported balance
After 2026-09-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-15 · Exercise / conversion · Disposed 76,452 · Balance 305,810 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F5: This option is fully vested and exercisable. |
| Common StockSEC Table I · non-derivative | IndirectBy Valhalla, LLC | 4,116 |
Reported balance
Holding disclosure · report date 2026-09-14 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 4,116 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 151,933 |
Reported balance
Holding disclosure · report date 2026-09-14 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 151,933 F4: These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.99 to $144.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.97 to $146.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4: These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F5: This option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2024 Filed Feb 13, 2024 21:13 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 522 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004682 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,516,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 16, 2024 Filed Jan 17, 2024 21:12 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 15,000 | $103.90 | $1,558,500.00 |
DisclosureSEC source: 0001127602-24-001416 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,516,063 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2023. Read SEC document |
| December 27, 2023 Filed Dec 28, 2023 13:00 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 45,000 | $100.01 | $4,500,450.00 |
DisclosureSEC source: 0001127602-23-030501 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,531,063 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.00 to $100.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 04, 2023 Filed Dec 5, 2023 21:07 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 309 | $79.31 | $24,507.84 |
DisclosureSEC source: 0001127602-23-028857 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,576,063 F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:07 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 651 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-028857 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,865 Underlying: Common Stock · 651 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:07 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 651 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-028857 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,576,372 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| November 29, 2023 Filed Nov 30, 2023 21:11 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 1,136 | $79.81 | $90,665.52 |
DisclosureSEC source: 0001127602-23-028465 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,575,721 F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| November 28, 2023 Filed Nov 30, 2023 21:11 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 2,411 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-028465 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,411 Underlying: Common Stock · 2,411 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: 50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. Read SEC document |
| November 28, 2023 Filed Nov 30, 2023 21:11 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,411 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-028465 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,576,857 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| November 10, 2023 Filed Nov 13, 2023 21:02 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 263 | $68.76 | $18,083.88 |
DisclosureSEC source: 0001127602-23-027222 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,574,446 F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| November 09, 2023 Filed Nov 13, 2023 21:02 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 522 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-027222 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,612 Underlying: Common Stock · 522 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| November 09, 2023 Filed Nov 13, 2023 21:02 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 522 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-027222 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,574,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| September 15, 2023 Filed Sep 18, 2023 20:06 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 15,000 | $112.99 | $1,694,850.00 |
DisclosureSEC source: 0001127602-23-024300 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,574,187 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2023. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 20:08 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 320 | $111.44 | $35,659.52 |
DisclosureSEC source: 0001127602-23-023774 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,589,187 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 20:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 652 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-023774 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,516 Underlying: Common Stock · 652 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 20:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 652 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-023774 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,589,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 29, 2023 Filed Aug 30, 2023 20:07 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 1,135 | $115.01 | $130,541.57 |
DisclosureSEC source: 0001127602-23-023416 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,588,855 F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| August 28, 2023 Filed Aug 30, 2023 20:07 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 2,411 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-023416 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,822 Underlying: Common Stock · 2,411 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: 50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. Read SEC document |
| August 28, 2023 Filed Aug 30, 2023 20:07 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,411 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-023416 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,589,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 21:16 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 15,000 | $100.00 | $1,500,000.00 |
DisclosureSEC source: 0001127602-23-022963 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,587,579 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2023. Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 20:18 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 247 | $102.53 | $25,325.26 |
DisclosureSEC source: 0001127602-23-022369 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,602,579 F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 20:18 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 523 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-022369 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,134 Underlying: Common Stock · 523 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 20:18 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 523 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-022369 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,602,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 17, 2023 Filed Jul 18, 2023 20:35 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 15,000 | $120.60 | $1,809,000.00 |
DisclosureSEC source: 0001127602-23-020950 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,602,303 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2023. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:10 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 15,000 | $125.93 | $1,888,950.00 |
DisclosureSEC source: 0001127602-23-018859 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,617,303 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2023. Read SEC document |
| June 02, 2023 Filed Jun 5, 2023 20:16 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 309 | $130.32 | $40,269.87 |
DisclosureSEC source: 0001127602-23-017826 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,632,303 F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:16 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 651 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-017826 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,168 Underlying: Common Stock · 651 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:16 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 651 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-017826 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,632,612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 30, 2023 Filed May 31, 2023 20:21 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 1,181 | $124.95 | $147,568.78 |
DisclosureSEC source: 0001127602-23-017228 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,631,961 F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| May 26, 2023 Filed May 31, 2023 20:21 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 2,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-017228 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,233 Underlying: Common Stock · 2,410 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: 50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 26, 2023 Filed May 31, 2023 20:21 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,410 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-017228 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,633,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 10, 2023 Filed May 11, 2023 20:09 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 250 | $133.37 | $33,343.58 |
DisclosureSEC source: 0001127602-23-015238 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,630,732 F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| May 09, 2023 Filed May 11, 2023 20:09 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 522 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-015238 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,657 Underlying: Common Stock · 522 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| May 09, 2023 Filed May 11, 2023 20:09 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 522 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-015238 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,630,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:27 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 1,177 | $136.43 | $160,582.70 |
DisclosureSEC source: 0001127602-23-008715 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,630,460 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:31 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 1,072 | $138.03 | $147,963.23 |
DisclosureSEC source: 0001127602-23-008449 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,629,031 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:27 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 2,606 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-008715 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,819 Underlying: Common Stock · 2,606 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:27 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-008715 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,631,637 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:31 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 9,768 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-008449 · form4.xml · derivative · entry 7 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,768 Underlying: Common Stock · 9,768 shares Expires not disclosed F6 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award will vest on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F6 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award will vest on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:31 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 37,217 | $0.00 Strike: $138.81 | $0.00 |
DisclosureSEC source: 0001127602-23-008449 · form4.xml · derivative · entry 6 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,217 Underlying: Common Stock · 37,217 shares Expires 2033-02-28 F5 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:31 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 2,410 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-008449 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,643 Underlying: Common Stock · 2,410 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: 50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:31 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-008449 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,630,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 10, 2023 Filed Feb 13, 2023 21:14 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 245 | $163.90 | $40,155.97 |
DisclosureSEC source: 0001127602-23-004851 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,627,693 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 21:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 522 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-004851 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,179 Underlying: Common Stock · 522 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 21:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 522 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-004851 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,627,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| November 29, 2022 Filed Nov 30, 2022 21:05 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 1,085 | $173.80 | $188,575.82 |
DisclosureSEC source: 0001127602-22-026544 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,627,416 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| November 28, 2022 Filed Nov 30, 2022 21:05 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 2,410 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026544 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,053 Underlying: Common Stock · 2,410 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: 50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. Read SEC document |
| November 28, 2022 Filed Nov 30, 2022 21:05 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026544 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,628,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 21:44 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 231 | $165.59 | $38,251.17 |
DisclosureSEC source: 0001127602-22-025500 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,626,091 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 21:44 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 522 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025500 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,701 Underlying: Common Stock · 522 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.